JP2023500701A5 - - Google Patents

Info

Publication number
JP2023500701A5
JP2023500701A5 JP2022525998A JP2022525998A JP2023500701A5 JP 2023500701 A5 JP2023500701 A5 JP 2023500701A5 JP 2022525998 A JP2022525998 A JP 2022525998A JP 2022525998 A JP2022525998 A JP 2022525998A JP 2023500701 A5 JP2023500701 A5 JP 2023500701A5
Authority
JP
Japan
Prior art keywords
antibody
region
antigen
approximately
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500701A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/081389 external-priority patent/WO2021089850A1/en
Publication of JP2023500701A publication Critical patent/JP2023500701A/ja
Publication of JP2023500701A5 publication Critical patent/JP2023500701A5/ja
Pending legal-status Critical Current

Links

JP2022525998A 2019-11-06 2020-11-06 抗体変種の組み合わせおよびその使用 Pending JP2023500701A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201901296 2019-11-06
DKPA201901296 2019-11-06
PCT/EP2020/081389 WO2021089850A1 (en) 2019-11-06 2020-11-06 Antibody variant combinations and uses thereof

Publications (2)

Publication Number Publication Date
JP2023500701A JP2023500701A (ja) 2023-01-10
JP2023500701A5 true JP2023500701A5 (https=) 2023-11-10

Family

ID=73449012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525998A Pending JP2023500701A (ja) 2019-11-06 2020-11-06 抗体変種の組み合わせおよびその使用

Country Status (4)

Country Link
US (1) US20220411529A1 (https=)
EP (1) EP4055046A1 (https=)
JP (1) JP2023500701A (https=)
WO (1) WO2021089850A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51666A (fr) * 2018-01-24 2020-12-02 Genmab Bv Variants polypeptidiques et leurs utilisations
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
AU2022369298A1 (en) * 2021-10-20 2024-06-06 Janssen Biotech, Inc. Biosynthetic biparatopic or bispecific binding molecules with enhanced effector functions

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
CN109476737A (zh) 2015-12-01 2019-03-15 根马布有限公司 抗dr5抗体及其使用方法
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
MA51666A (fr) * 2018-01-24 2020-12-02 Genmab Bv Variants polypeptidiques et leurs utilisations

Similar Documents

Publication Publication Date Title
JP7321303B2 (ja) Cd3結合抗体
US11999801B2 (en) Multispecific antibodies
US9540442B2 (en) Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
EP2760891B1 (en) Hybrid constant regions
JP7793679B2 (ja) ヒトTim-3に対するモノクローナル抗体
US20190263904A1 (en) Cd3 binding antibodies
JP2012526558A5 (https=)
JP2006521085A (ja) Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
JP2021522303A5 (https=)
JP2023500701A5 (https=)
AU2022278013A1 (en) Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
WO2015146437A1 (ja) 高機能性IgG2型二重特異性抗体
JP7689116B2 (ja) Pd1およびvegfr2二重結合剤
JP2024518411A (ja) Cd47およびpd-l1に特異的に結合する二重特異性抗体
KR20250173554A (ko) 다발성 골수종의 치료 방법
US20250122299A1 (en) ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
KR20250173553A (ko) 다발성 골수종의 치료 방법
WO2023178253A2 (en) Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
HK40107381A (en) Cd3 binding antibodies
HK40078017A (en) Cd3 binding antibodies
CN116963775A (zh) 抗siglec-8抗体制剂
Stork Improvement of pharmacokinetics of small recombinant bispecific antibody molecules
NZ785574A (en) CD3 binding antibodies